开启最后“倒计时”，稳健横盘成劲方医药-B“入通”关键？

Core Viewpoint - The article discusses the imminent adjustment period for the Hong Kong Stock Connect, highlighting the potential inclusion of 31 new stocks, including Jinfang Pharmaceutical, which is expected to meet the entry criteria due to its stable market performance [1][2]. Group 1: Company Performance - Jinfang Pharmaceutical's average market capitalization during the review period is reported at HKD 10.296 billion, exceeding the threshold of HKD 9.242 billion by over HKD 1 billion, indicating a strong likelihood of inclusion in the upcoming adjustment [2]. - The stock experienced significant volatility post-IPO, with a peak increase of 115.79% from the issue price, followed by a decline of 29.31% over a month, reflecting market fluctuations and investor sentiment [3][10]. - After reaching a market cap below HKD 10 billion on October 22, the stock quickly stabilized, avoiding further price bubble risks, aided by its IPO structure which limited short-term selling pressure from retail investors [11]. Group 2: Market Context - The Hong Kong innovative drug sector has seen a substantial rally, with the Hang Seng Healthcare Index rising from a low of 2152.38 points to a high of 4726.41 points, marking a maximum increase of 119.59% over eight months [10]. - Jinfang Pharmaceutical's IPO was highly successful, with a subscription rate of 2662.79 times for the public offering, reflecting strong institutional interest in the KRAS inhibitor sector [10]. - The stock's performance is also influenced by broader market trends, as the Hang Seng Healthcare Index experienced an 11.05% correction in October, impacting investor behavior and contributing to Jinfang's price volatility [10]. Group 3: Technical Analysis - Following a significant drop on October 22, Jinfang Pharmaceutical's stock price rebounded sharply, indicating strong buying interest and a potential shift in market sentiment [4][6]. - The stock has entered a phase of stable horizontal consolidation, with a high concentration of shares held by investors, which reduces the likelihood of significant price fluctuations in the near term [6]. - The average cost of shares held by investors remains around HKD 37, which is significantly above the current market price, further discouraging selling and stabilizing the stock [6].